A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 389
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : HIV-2
Long Form : human immunodeficiency virus type 2
No. Year Title Co-occurring Abbreviation
2020 Antiretroviral Therapy for HIV-2 Infection in Non-Endemic Regions. NNRTIs
2020 Defective Strand-Displacement DNA Synthesis Due to Accumulation of Thymidine Analogue Resistance Mutations in HIV-2 Reverse Transcriptase. RTs, TAMs
2020 Performance evaluation of a laboratory developed PCR test for quantitation of HIV-2 viral RNA. qRT-PCR
2020 The stability of HIV-2 Vpx and Vpr proteins is regulated by the presence or absence of zinc-binding sites and poly-proline motifs with distinct roles. PPM
2020 Viral protein X unlocks the nuclear pore complex through a human Nup153-dependent pathway to promote nuclear translocation of the lentiviral genome. NPC, Nup153, SIV, Vpx
2019 HIV-2 (Human-Immunodeficiency Virus) : A Myriad of Myths - Presenting as Multiple Large Vessel Arterial Occlusions. ---
2019 HIV-2 Depletes CD4 T Cells through Pyroptosis despite Vpx-Dependent Degradation of SAMHD1. HLACs, SAMHD1
2019 Interference with SAMHD1 Restores Late Gene Expression of Modified Vaccinia Virus Ankara in Human Dendritic Cells and Abrogates Type I Interferon Expression. DCs, dNTP, HD, MVA, SAM, SIV, Vpx
2019 Lentiviral Vpx induces alteration of mammalian cell nuclear envelope integrity. SIV, SR-SIM
10  2018 A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa. ART, VL
11  2018 First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2). ART, IQR, PCR, pVL, uspVL
12  2018 HIV-2 Infection in a Migrant from Gambia: The History of the Disease Combined with Phylogenetic Analysis Revealed the Real Source of Infection. ASC
13  2017 A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. C-HR, HIV-1, SIV
14  2016 Expression Profiles of Vpx/Vpr Proteins Are Co-related with the Primate Lentiviral Lineage. PPM, SIV
15  2016 Hiv-2 molecular epidemiology. SIVsmm
16  2016 Human Immunodeficiency Virus Type 2 (HIV-2) Gag Is Trafficked in an AP-3 and AP-5 Dependent Manner. HIV
17  2016 Phylogenetic Analysis of Human Immunodeficiency Virus Type 2 Group B. ---
18  2016 Phylogenetic Insights into the Functional Relationship between Primate Lentiviral Reverse Transcriptase and Accessory Proteins Vpx/Vpr. dNTP, RT, SIVs
19  2016 SAMHD1 in Retroviral Restriction and Innate Immune Sensing--Should We Leash the Hound? DC, SAMHD1, SIV
20  2016 Single Amino Acid Substitution N659D in HIV-2 Envelope Glycoprotein (Env) Impairs Viral Release and Hampers BST-2 Antagonism. Env, FRET
21  2016 Two human immunodeficiency virus Type 2 cases in US blood donors including serologic, molecular, and genomic characterization of an epidemiologically unusual case. mNGS
22  2015 Buccal cancer in a female patient with human immunodeficiency virus-2 infection. SCC
23  2015 Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program. IQR, NPP, pVL
24  2015 HIV-1 and HIV-2 exhibit similar mutation frequencies and spectra in the absence of G-to-A hypermutation. HIV-1
25  2015 HIV-2 infects resting CD4+ T cells but not monocyte-derived dendritic cells. MDDCs
26  2015 Inclusion of human immunodeficiency virus Type 2 (HIV-2) in a multiplex transcription-mediated amplification assay does not affect detection of HIV-1 and hepatitis B and C virus genotypes: a multicenter performance evaluation study. HBV, HCV, IUs, LODs
27  2015 The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1. ART, NNRTIs, PIs
28  2014 Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection. RT
29  2014 Human immunodeficiency virus type 2 infections in Austria. HIV-1
30  2014 Moderate restriction of macrophage-tropic human immunodeficiency virus type 1 by SAMHD1 in monocyte-derived macrophages. HIV-1
31  2014 Novel inhibitors of human immunodeficiency virus type 2 infectivity. ---
32  2014 Phylogenetic analysis of human immunodeficiency virus type 2 isolated from Cuban individuals. ---
33  2014 Poly-proline motif in HIV-2 Vpx is critical for its efficient translation. PPM, SIVmac
34  2014 Rapid quantitative detection of Human immunodeficiency virus type 1 by a reverse transcription-loop-mediated isothermal amplification assay. CV, HCV, HIV-1, HTLV-1, RT-LAMP
35  2014 SAMHD1 specifically affects the antiviral potency of thymidine analog HIV reverse transcriptase inhibitors. dNTP, NRTI, RT, SAMHD1
36  2013 A twin-cysteine motif in the V2 region of gp120 is associated with SIV envelope trimer stabilization. ---
37  2013 An HIV type 2 case series in Italy: a phylogenetic analysis. ---
38  2013 Effect of complement on HIV-2 plasma antiviral activity is intratype specific and potent. AUC
39  2013 Evidence for a different susceptibility of primate lentiviruses to type I interferons. CA, HIV-1, SIVmac, Trim5alpha, vDNA, VNCs
40  2013 Frequent intratype neutralization by plasma immunoglobulin a identified in HIV type 2 infection. HIV-D, IgA
41  2013 High level of HIV-2 false positivity in KwaZulu-Natal province: a region of South Africa with a very high HIV-1 subtype C prevalence. ---
42  2013 HIV-2EU: supporting standardized HIV-2 drug resistance interpretation in Europe. ---
43  2013 Inhibition of CUL4A Neddylation causes a reversible block to SAMHD1-mediated restriction of HIV-1. SIVmac
44  2013 Multiple platforms of a HIV-2 derived lentiviral vector for expanded utility. LV, MCS
45  2013 Validation and clinical use of a sensitive HIV-2 viral load assay that uses a whole virus internal control. IU
46  2013 When phylogenetic analysis complements the epidemiological investigation: a case of HIV-2 infection, Italy. ---
47  2012 Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression. hs-CRP, IL-6, sCD14
48  2012 Electrostatic potential of human immunodeficiency virus type 2 and rhesus macaque simian immunodeficiency virus capsid proteins. Rh, SIVmac, SIVmac239, SIVsm
49  2012 HIV-2 genome dimerization is required for the correct processing of Gag: a second-site reversion in matrix can restore both processes in dimerization-impaired mutant viruses. DIS, Psi, SL1
50  2012 Human immunodeficiency virus type-2-A milder, kinder virus: an update. HIV-1
51  2012 Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool. ---
52  2012 Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A. HIV-2A
53  2012 Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1. NAc
54  2012 The Vpx lentiviral accessory protein targets SAMHD1 for degradation in the nucleus. CRL4, NLS, SAMHD1, SIVs, Vpx
55  2012 Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens. ---
56  2012 Validation for clinical use of a novel HIV-2 plasma RNA viral load assay using the Abbott m2000 platform. SD, VL
57  2011 A case of Italian HIV type 2 infection: a genetic analysis. ---
58  2011 A single amino acid of human immunodeficiency virus type 2 capsid protein affects conformation of two external loops and viral sensitivity to TRIM5alpha. CA, CM
59  2011 Crystal structure of the HIV-2 neutralizing Fab fragment 7C8 with high specificity to the V3 region of gp125. ---
60  2011 Human immunodeficiency virus type 2 in two Saudi families. AIDS
61  2011 Immune reconstitution and inflammatory syndrome due to disseminated tuberculosis in a case of human immunodeficiency virus 2 infection. ATT
62  2011 Mechanisms of human immunodeficiency virus type 2 RNA packaging: efficient trans packaging and selection of RNA copackaging partners. ---
63  2011 Update on human immunodeficiency virus (HIV)-2 infection. HIV
64  2011 Variable prevalence and functional diversity of the antiretroviral restriction factor TRIMCyp in Macaca fascicularis. CypA, FIV
65  2010 Interaction of Vpx and apolipoprotein B mRNA-editing catalytic polypeptide 3 family member A (APOBEC3A) correlates with efficient lentivirus infection of monocytes. APOBEC3A
66  2010 Multiple sites in the N-terminal half of simian immunodeficiency virus capsid protein contribute to evasion from rhesus monkey TRIM5alpha-mediated restriction. CA, CM, Rh, SIVmac
67  2010 Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy. NAbs, rpC2-C3
68  2009 A neutralization assay for HIV-2 based on measurement of provirus integration by duplex real-time PCR. ---
69  2009 Betulinic acid derivatives as human immunodeficiency virus type 2 (HIV-2) inhibitors. ---
70  2009 Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa. ARV, NRTI, PIs
71  2009 HIV-1 superinfection in an HIV-2-infected woman with subsequent control of HIV-1 plasma viremia. ---
72  2009 Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. Env, HIV-1
73  2009 Impact of a single amino acid in the variable region 2 of the Old World monkey TRIM5alpha SPRY (B30.2) domain on anti-human immunodeficiency virus type 2 activity. ---
74  2009 Molecular characterization of the env gene of two CCR5/CXCR4-independent human immunodeficiency 2 primary isolates. HIV-1
75  2009 Production, purification, crystallization and preliminary X-ray diffraction analysis of the HIV-2-neutralizing V3 loop-specific Fab fragment 7C8. ---
76  2009 Randomization and in vivo selection reveal a GGRG motif essential for packaging human immunodeficiency virus type 2 RNA. Psi, SL1
77  2009 Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants. ART, HIV-1, ZDV
78  2008 A lentiviral vector with novel multiple cloning sites: stable transgene expression in vitro and in vivo. GFP, LV, MCS
79  2008 Characterization of simian immunodeficiency virus SIVSM/human immunodeficiency virus type 2 Vpx function in human myeloid cells. DCs, SM
80  2008 Comparison of anti-viral activity of rhesus monkey and cynomolgus monkey TRIM5alphas against human immunodeficiency virus type 2 infection. CM, OWM, Rh
81  2008 Full-length genome characterization of an HIV type 2 isolate from India. LTR, ORF
82  2008 Gag-specific CD4+ T-cell frequency is inversely correlated with proviral load and directly correlated with immune activation in infection with human immunodeficiency virus type 2 (HIV-2) but not HIV-1. ---
83  2008 Higher homologous and lower cross-reactive Gag-specific T-cell responses in human immunodeficiency virus type 2 (HIV-2) than in HIV-1 infection. ---
84  2008 HIV-2 amino acid substitutions in Gag and Env proteins occurring simultaneously with viral load upsurge in a drug-naive patient. ---
85  2008 Hsp40 facilitates nuclear import of the human immunodeficiency virus type 2 Vpx-mediated preintegration complex. GST, PIC, siRNA
86  2008 In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. ---
87  2008 Isolation of a new HIV-2 group in the US. SIV
88  2008 Mutagenesis of Gln294 of the reverse transcriptase of human immunodeficiency virus type-2 and its effects on the ribonuclease H activity. HIV-1, RNase H, RTs, WT
89  2008 Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006. ---
90  2008 Structural evidence for effectiveness of darunavir and two related antiviral inhibitors against HIV-2 protease. HIV-1, PR
91  2008 Vpx is critical for reverse transcription of the human immunodeficiency virus type 2 genome in macrophages. MDMs
92  2007 A single amino acid of the human immunodeficiency virus type 2 capsid affects its replication in the presence of cynomolgus monkey and human TRIM5alphas. CA, CM, OWM
93  2007 An extended stem-loop 1 is necessary for human immunodeficiency virus type 2 replication and affects genomic RNA encapsidation. pal
94  2007 Dendritic cells are less susceptible to human immunodeficiency virus type 2 (HIV-2) infection than to HIV-1 infection. DCs, HIV-1, mDCs, pDCs
95  2007 Development and evaluation of an oligonucleotide ligation assay for detection of drug resistance-associated mutations in the human immunodeficiency virus type 2 pol gene. OLA
96  2007 Dimerisation of HIV-2 genomic RNA is linked to efficient RNA packaging, normal particle maturation and viral infectivity. DIS, pal, Psi, SL1
97  2007 Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection. ---
98  2007 Efficient thymopoiesis contributes to the maintenance of peripheral CD4 T cells during chronic human immunodeficiency virus type 2 infection. ---
99  2007 Mechanisms of CD4 downregulation by the Nef and Vpu proteins of primate immunodeficiency viruses. AIDS, HIV-1, SIV
100  2007 Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. APV, IDV, NFV, PI, PR, TPV